Showing 1 - 10 of 945
Our study puts special attention to the fact that R&D cooperations in the pharmaceutical industry are formed at different stages throughout the drug development process. We study if the timing to engage in R&D cooperations in the pharmaceutical industry has different impacts on the technology...
Persistent link: https://www.econbiz.de/10010229875
Persistent link: https://www.econbiz.de/10003499685
This paper develops a model of the war against illegal drugs in both producer and consumer countries. The paper studies the trade-off faced by the government of the drug consumer country between prevention policies (aimed at reducing the demand for drugs) and enforcement policies (aimed at...
Persistent link: https://www.econbiz.de/10003790762
a larger share of the patent rent is spent on marketing, relative to R&D. -- Marketing ; Research & Development …
Persistent link: https://www.econbiz.de/10003771873
This paper analyses the causal impact of Intellectual Property Rights (IPR) on pharmaceutical innovation in a panel of 74 countries. The identification strategy exploits the different timing across countries of two sets of IPR reforms. Domestic innovation is measured as citation-weighted...
Persistent link: https://www.econbiz.de/10011509446
Longitudinal, disease-level data are used to analyze the impact of pharmaceutical innovation on longevity (mean age at death), hospital utilization, and medical expenditure in Greece during the period 1995 - 2010. The estimates indicate that pharmaceutical innovation increased mean age at death...
Persistent link: https://www.econbiz.de/10010473542
In the European Union, medicines are regulated products subject to both single market (e.g., regional exhaustion of property rights) and country specific health care regulations (e.g., medicines pricing). This gives rise to parallel trade (PT), a phenomenon that takes place when a patented...
Persistent link: https://www.econbiz.de/10010477153
companies to direct their R&D toward marketing products that are "follow-on" drugs of already existing drugs, rather than toward …
Persistent link: https://www.econbiz.de/10011406575
This paper provides insights into the determinants of bargaining power and how they affect drug prices. Our data show that drug prices vary across buyers and time periods. We estimate a structural bargaining model where drug suppliers and buyers engage in bilateral bargaining over drug prices....
Persistent link: https://www.econbiz.de/10012138768
This paper reports the results from a statistical analysis of pharmaceutical price negotiations in Germany, where the pricing system was changed in 2011 in order to tie prices more to the benefits of the pharmaceuticals. A multiple linear regression of 187 pharmaceuticals which were assessed...
Persistent link: https://www.econbiz.de/10012119750